Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Allergic Reactions02:06

Allergic Reactions

26.3K
Overview
26.3K
Hypersensitivities01:30

Hypersensitivities

7.2K
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
7.2K
Cross-reactivity00:42

Cross-reactivity

28.7K
Overview
28.7K
Allergic Reactions: Anaphylaxis01:30

Allergic Reactions: Anaphylaxis

278
Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin,...
278
Allergic Drug Reactions01:27

Allergic Drug Reactions

1.6K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.6K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

2.3K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effectiveness and Safety of Dupilumab in Patients with Chronic Rhinosinusitis with Nasal Polyps and Associated T2 Comorbidities: One-Year Real Life Round.

Journal of clinical medicine·2026
Same author

Use of lactic acid bacteria to reduce the IgE-reactivity of the arginine kinase allergen from the edible insect Hermetia illucens.

Food research international (Ottawa, Ont.)·2026
Same author

Edible Insects and Allergenic Potential: An Observational Study About In Vitro IgE-Reactivity to Recombinant Pan-Allergens of the Black Soldier Fly (<i>Hermetia illucens</i>) in Patients Sensitized to Crustaceans and Mites.

International journal of molecular sciences·2025
Same author

Gender and Allergy: Mechanisms, Clinical Phenotypes, and Therapeutic Response-A Position Paper from the Società Italiana di Allergologia, Asma ed Immunologia Clinica (SIAAIC).

International journal of molecular sciences·2025
Same author

Personalization of therapy for patients with eosinophilic esophagitis.

Expert review of clinical immunology·2025
Same author

Exploring allergy to novel foods in the Western countries: current and future perspectives.

Expert review of clinical immunology·2025
Same journal

Anti-PD-(L)1 plus chemotherapy in advanced PD-L1-negative nonsquamous non-small cell lung cancer: a systematic review and meta-analysis.

Immunotherapy·2026
Same journal

Anti-TIGIT therapies in digestive cancers: from immune evasion to precision immunotherapy.

Immunotherapy·2026
Same journal

CAR cellular therapies for acute myeloid leukemia: current landscape and future directions.

Immunotherapy·2026
Same journal

Recent advances in bispecific natural killer cell engagers for cancer immunotherapy.

Immunotherapy·2026
Same journal

Exploring global research trends in sublingual immunotherapy of allergic rhinitis: a comprehensive bibliometric analysis.

Immunotherapy·2026
Same journal

Autoimmune encephalitis and axonal polyradiculoneuropathy following therapy with adalimumab and secukinumab: a case report and literature review.

Immunotherapy·2026
See all related articles

Related Experiment Video

Updated: Apr 28, 2026

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

11.3K

Arguing the misconceptions in allergen-specific immunotherapy.

Erminia Ridolo1, Marcello Montagni, Laura Bonzano

  • 1Department of Clinical and Experimental Medicine, University of Parma, via Gramsci 14, 43100 Parma, Italy.

Immunotherapy
|June 5, 2014
PubMed
Summary
This summary is machine-generated.

Allergen immunotherapy (AIT) is effective and safe, but concerns about contraindications and allergen extract quality limit its use. Addressing these issues can improve AIT acceptance and patient outcomes.

Keywords:
allergen immunotherapycardiovascular medicationelderly patientmalignanciesmisconceptionpolysensitizationpregnancyquality of allergen extract

More Related Videos

Basophil Activation Test for Allergy Diagnosis
07:22

Basophil Activation Test for Allergy Diagnosis

Published on: May 31, 2021

9.9K
Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E sIgE
07:10

Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E sIgE

Published on: April 21, 2019

15.9K

Related Experiment Videos

Last Updated: Apr 28, 2026

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

11.3K
Basophil Activation Test for Allergy Diagnosis
07:22

Basophil Activation Test for Allergy Diagnosis

Published on: May 31, 2021

9.9K
Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E sIgE
07:10

Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E sIgE

Published on: April 21, 2019

15.9K

Area of Science:

  • Immunology
  • Allergy and Clinical Immunology
  • Pharmacology

Background:

  • Allergen immunotherapy (AIT) demonstrates established efficacy and safety through meta-analyses.
  • Several factors, often lacking robust data, impede broader AIT adoption.
  • Misconceptions regarding contraindications and allergen extract quality require clarification.

Purpose of the Study:

  • To critically evaluate purported contraindications to AIT.
  • To address concerns about allergen extract quality and standardization.
  • To promote wider acceptance of AIT by clarifying its benefits and risks.

Main Methods:

  • Literature review and critical analysis of existing data on AIT contraindications.
  • Examination of factors influencing AIT use, including comorbidities and drug interactions.
  • Assessment of the impact of allergen extract variability on AIT outcomes.

Main Results:

  • Many commonly cited contraindications for AIT lack strong scientific support and require case-by-case risk-benefit assessment.
  • Comorbidities (autoimmune diseases, malignancies), certain medications (beta-blockers, ACE inhibitors), pregnancy, age, asthma severity, and polysensitization warrant careful consideration.
  • Variability in the quality of allergen extracts contributes to misconceptions and hinders AIT's general acknowledgment.

Conclusions:

  • Re-evaluation of contraindications based on current evidence is necessary for optimal AIT application.
  • Standardization and improved characterization of allergen extracts are crucial for enhancing AIT's reliability and acceptance.
  • Addressing these limitations will facilitate the broader implementation of AIT as a valuable treatment for allergic diseases.